Tech Company Financing Transactions
ViaCyte Funding Round
On 6/11/2021, ViaCyte raised $45 million in Series D investment from Adage Capital Management, ARTIS Ventures and Asymmetry Capital Management.
Transaction Overview
Company Name
Announced On
6/11/2021
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series D
Investors
Proceeds Purpose
The money will help ViaCyte advance its phase 2 clinical study on PEC-Encap, a treatment made up of pancreatic islet precursor cells inside a novel membrane.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3550 General Atomics Ct.
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
ViaCyte is a preclinical therapeutic company focused on diabetes. Our therapy is based on pancreatic beta cell progenitors (Pro-Islet) derived from human pluripotent stem cells. These cells are implanted using a durable and retrievable encapsulation device.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 6/11/2021: Synthekine venture capital transaction
Next: 6/11/2021: Electric Gamebox venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs